The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis
Abstract
OBJECTIVE: To review the effect of risedronate on bone density and fractures in postmenopausal women. DATA SOURCES: We searched MEDLINE from 1966 to the end of 2000 and examined citations of relevant articles and the proceedings of international osteoporosis meetings. STUDY SELECTION: We included eight randomized, placebo-controlled trials of postmenopausal women receiving risedronate or placebo with a follow-up of at least one year and providing data on bone density or fracture rate. DATA EXTRACTION: For each trial, two independent reviewers assessed the methodological quality and abstracted data. DATA SYNTHESIS: The major methodological limitation of the trials was the loss to follow-up, which was over 20% in most trials and over 35% in the largest study. However, the magnitude of the treatment effect was unrelated to loss to follow-up, and in one of the largest trials, more high-risk patients were lost to follow-up in the control than in the treatment group. The pooled relative risk (RR) for vertebral fractures in women given 2.5 mg or more of risedronate was 0.64 [95% confidence interval (CI) 0.54, 0.77]. The pooled RR of nonvertebral fractures in patients given 2.5 mg or more of risedronate was 0.73 (95% CI 0.61, 0.87). Risedronate produced positive effects on the percentage change in bone density of the lumbar spine, combined forearm, and femoral neck that were generally larger with the 5-mg daily dose than with cyclical administration or the 2.5-mg dose. The pooled estimate of the difference in percentage change between 5 mg risedronate and placebo after the final year of treatment (1.5-3 yr) was 4.54% (95% CI 4.12, 4.97) for the lumbar spine, and 2.75% (95% CI 2.32, 3.17) at the femoral neck. CONCLUSIONS: Risedronate substantially reduces the risk of both vertebral and nonvertebral fractures. This fracture reduction is accompanied by an increase in bone density of the lumbar spine and femoral neck in both early postmenopausal women and those with established osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Review papers : The statistical basis of meta-analysis
Fleiss, J. (1993) · Statistical Methods in Medical Research · doi:10.1177/096228029300200202 · Cited by 1,281
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Reszka, A. A., Halasy-Nagy, J. M., Masarachia, P. J., & Rodan, G. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34967 · Cited by 254
Mortensen, L., Charles, P., Bekker, P. J., Digennaro, J., & Johnston, C. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4586 · Cited by 220
Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & Reginster for the bmd-mn Study Grou, J.-Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6603 · Cited by 198
Cited by
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials
Pildal, J., Hrobjartsson, A., Jorgensen, K., Hilden, J., Altman, D., & Gotzsche, P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym087 · Cited by 472
Bone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
Metadata
- Authors
- Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Shea, B., Wells, G., & Guyatt, G.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2002-08
- Volume
- 23
- Issue
- 4
- Pages
- 517-523
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2039548369
- Cited by
- 281
- References
- 13
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis. https://app.cochat.ai/papers/10.1210/er.2001-3002
- The paper
- Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Shea, B., Wells, G., & Guyatt, G. (2002). III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis. Endocrine Reviews. https://doi.org/10.1210/er.2001-3002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.